Skip to main content

H.C. Wainwright Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)

Tipranks - Tipranks - Mon Nov 10, 2025

In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Viridian Therapeutics, with a price target of $34.00.

Meet Your ETF AI Analyst

Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes. According to TipRanks, Tsao has an average return of 22.0% and a 53.85% success rate on recommended stocks.

In addition to H.C. Wainwright, Viridian Therapeutics also received a Buy from Goldman Sachs’s Richard Law CFA in a report issued on November 6. However, on November 7, TR | OpenAI – 4o reiterated a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).

See today’s best-performing stocks on TipRanks >>

Based on Viridian Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.57 million and a GAAP net loss of $34.6 million. In comparison, last year the company earned a revenue of $86 thousand and had a GAAP net loss of $76.69 million

Read More on VRDN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).